We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

71 hedge funds and large institutions have $202M invested in AEON Biopharma in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $192M → $202M (+$10.3M)

0.05% more ownership

Funds ownership: 0.99% → 1.04% (+0.05%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

3% less funds holding

Funds holding: 73 → 71 (-2)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$9.74M
2
SC
Sculptor Capital
New York
+$4.67M
3
SCM
Saba Capital Management
New York
+$4.21M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.47M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$2.34M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$4.99M
2
Blackstone Inc
Blackstone Inc
New York
-$4.48M
3
Wells Fargo
Wells Fargo
California
-$2.76M
4
MP
Mangrove Partners
Connecticut
-$2.06M
5
ACA
Arena Capital Advisors
California
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCC
26
Spring Creek Capital
Kansas
$2.44M – – –
Alyeska Investment Group
27
Alyeska Investment Group
Illinois
$2.35M +$2.34M +3,333 New
Nomura Holdings
28
Nomura Holdings
Japan
$2.21M +$2.2M +3,132 New
GCL
29
Glazer Capital LLC
New York
$2.09M +$2.05M +2,928 +8,133%
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
$1.96M – – –
CF
31
Cantor Fitzgerald
New York
$1.67M +$877K +1,250 +112%
DCM
32
Dupont Capital Management
Delaware
$1.47M – – –
FCM
33
Farallon Capital Management
California
$1.47M – – –
AR
34
Advisory Research
Illinois
$1.46M – – –
LOAMU
35
Lombard Odier Asset Management (USA)
New York
$1.22M – – –
JP Morgan Chase
36
JP Morgan Chase
New York
$1.01M -$1.66M -2,361 -62%
AA
37
AQR Arbitrage
Connecticut
$1.01M -$217K -310 -18%
CL
38
CSS LLC
Illinois
$997K -$991K -1,413 -50%
Janus Henderson Group
39
Janus Henderson Group
United Kingdom
$989K +$984K +1,403 New
MCM
40
Moore Capital Management
New York
$978K – – –
AC
41
Athos Capital
Hong Kong
$873K – – –
CC
42
Centiva Capital
New York
$802K +$505K +720 +172%
SSA
43
Schonfeld Strategic Advisors
New York
$790K -$49.1K -70 -6%
KCM
44
Kawa Capital Management
Florida
$684K – – –
ACA
45
Arena Capital Advisors
California
$599K -$1.84M -2,617 -75%
WAM
46
Wolverine Asset Management
Illinois
$555K +$544K +775 +5,962%
EH
47
EMG Holdings
Connecticut
$520K -$213K -303 -29%
HighTower Advisors
48
HighTower Advisors
Illinois
$513K -$142K -203 -22%
HF
49
HRT Financial
New York
$502K +$3.51K +5 +0.7%
COPPSERS
50
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$489K – – –
1
2
3 4

AEON Hedge Fund Activity: Q1 2022 in Review

71 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2022, worth a combined $202M — up 5.4% from $192M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of AEON and 8 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 12 added.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $9.74M. The largest seller was UBS O'Connor, exiting entirely with an estimated $4.99M sold.

  • 71 institutional investors held AEON Biopharma (AEON) as of Q1 2022, down from 73 in Q4 2021.
  • Funds reported $202M of AEON Biopharma stock for Q1 2022, up 5.4% quarter-over-quarter.
  • 8 funds opened new AEON Biopharma positions in Q1 2022 and 10 closed out, a net change of -2 holders.
  • The largest AEON Biopharma buyer in Q1 2022 was Aristeia Capital, an estimated $9.74M added.
  • The largest AEON Biopharma seller in Q1 2022 was UBS O'Connor, an estimated $4.99M sold.

Based on aggregated 13F filings for Q1 2022.